Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Progress and Prospect on Technology and Products Development of Tumor Immunotherapy

LU Shan;LI Su-ning;FAN Hong;China National Center for Biotechnology Development;  
In recent years,the breaking-through progress has been made in the research of tumor immunotherapy,and the explosive growth has been obtained in the RD of related technology and product. Great investment has been made by many Biotech Corp and pharmaceutical companies,the international competition is becoming increasingly fierce. The emerging question confronting China is how to seize the opportunities and stand out in the international competition. An overall understanding of the development situation of the field through a comprehensive analysis of the main products,technology and future research direction of the dendritic cell-based vaccine and adoptive cell transfer therapy( ACT) featured are gtiven by CAR-T and TCR-T and anti-tumor immune checkpoint inhibitors targeted to PD-1 / PD-L1,and reference for RD work through the analysis of the technical features and development trend of immunotherapy represented by the above mentioned three approaches are provided. And for the RD situation and the existing problems in this field,suggestions such as strengthening the overall planning,focusing on basic research,emphasizing the patent protection,enhancing the scientific supervision,are put forward to provide a reference on how to make a better development of China 's tumor immune therapy.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved